FDA Hears Concerns About The Unregulated CBD Market

  • Forbes | by: Holly Lawrence |
  • 06/04/2019 12:00 AM
A Call for Regulatory Oversight

The FDA hearing’s first speaker, Peter Pitts, president of the Center for Medicine in the Public Interest and a former FDA associate commissioner, set the theme. “The absence to date, of advanced regulatory thinking relative to CBD has resulted in a maelstrom of false claims and shoddy quality standards,” Pitts said.

He called out “aggressive and misleading marketing campaigns” for CBD products, and urged, “It’s time for the proponents of CBD, including many highly vocal patients, physicians, pharmacists, manufacturers and distributors, to become part of the solution.

“Quality must always trump corporate convenience,” Pitts said, expressing the need for production quality oversight.

He also described a lack of a dosing schedule for CBD products. “When people are told to use CBD by physicians, pharmacists, friends or internet experts, they are not given any peer-reviewed guidelines on how they should take it or in what amounts — something that should never happen,” Pitts said.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Truth vs. Tort
  • CMPI
  • 07/18/2024 12:00 AM

Truth vs. Tort

New litigation alleging preterm infant formula and human milk fortifiers cause NEC distorts the facts and ignores what th...  Read more

New CMPI Book: And Nothing But the Truth

New CMPI Book: And Nothing But the Truth

Healthcare evolution, in technology and policy, is a never-ending parade of complicated and contradictory truths. This bo...  Read more

Tort bar’s newest collateral damage: Preterm babies

Tort bar’s newest collateral damage: Preterm babies

Lawsuits allege links between intestinal disease, infant formula and human milk fortifiers...  Read more

DRUGWONKS BLOG